See more : WiseTech Global Limited (WTC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Salona Global Medical Device Corporation (LNDZF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salona Global Medical Device Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Guangdong Ellington Electronics Technology Co.,Ltd (603328.SS) Income Statement Analysis – Financial Results
- Nevada Zinc Corporation (GDSKF) Income Statement Analysis – Financial Results
- Shah Alloys Limited (SHAHALLOYS.NS) Income Statement Analysis – Financial Results
- FGV Holdings Berhad (5222.KL) Income Statement Analysis – Financial Results
- Oak View Bankshares, Inc. (OAKV) Income Statement Analysis – Financial Results
Salona Global Medical Device Corporation (LNDZF)
About Salona Global Medical Device Corporation
Salona Global Medical Device Corporation, through its subsidiaries, engages in the production and sale of medical devices and products in the United States. The company's medical devices are used for pain management, cold and hot therapy, transcutaneous electronic nerve and neuromuscular electrical stimulation, pulsed electromagnetic field technology, and ultrasound therapy. It also offers wearable technology and products that are used to enhance physical stability. The company was formerly known as Brattle Street Investment Corp. and changed its name to Salona Global Medical Device Corporation in December 2020. Salona Global Medical Device Corporation was incorporated in 2013 and is headquartered in Del Mar, California.
| Metric | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.63M | 18.31M | -33.55K | 352.13K | 3.15M | 3.94M | 3.94M | 2.10M | 359.01K |
| Cost of Revenue | 40.09M | 12.35M | 12.35M | 372.46K | 61.85K | 6.77M | 825.30K | 945.80K | 21.37K |
| Gross Profit | 22.53M | 5.96M | -12.38M | -20.33K | 3.09M | -2.83M | 3.12M | 1.16M | 337.64K |
| Gross Profit Ratio | 35.98% | 32.56% | 36,914.62% | -5.77% | 98.03% | -71.87% | 79.08% | 55.02% | 94.05% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.16M | 5.73M | 990.28K | 1.71M | 3.83M | 4.97M | 5.09M | 3.84M | 1.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 11.57K | 3.07K | 296.62K | 540.74K | 0.00 |
| SG&A | 24.16M | 5.73M | 990.28K | 1.71M | 3.85M | 4.97M | 5.39M | 4.38M | 1.49M |
| Other Expenses | 3.90M | 233.82K | -1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.05M | 5.96M | 990.28K | 1.71M | 3.85M | 4.97M | 5.39M | 4.38M | 1.49M |
| Cost & Expenses | 68.15M | 18.31M | 990.28K | 2.08M | 3.91M | 11.74M | 6.21M | 5.33M | 1.51M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.64M | 388.07K | 388.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.48M | 841.77K | 841.77K | 54.52K | 256.04K | 276.73K | 83.19K | 1.27K | -460.62K |
| EBITDA | -8.40M | -3.24M | -1.02M | -1.63M | -504.53K | -7.41M | 4.22M | -3.28M | -1.38M |
| EBITDA Ratio | -13.41% | -17.71% | 3,051.93% | -464.06% | -16.03% | -188.01% | 106.97% | -156.23% | -385.19% |
| Operating Income | -5.52M | -4.84M | -1.02M | -1.69M | -760.57K | -7.68M | -8.67M | -3.17M | -922.25K |
| Operating Income Ratio | -8.82% | -26.42% | 3,051.93% | -479.55% | -24.17% | -195.04% | -219.77% | -150.58% | -256.89% |
| Total Other Income/Expenses | -10.02M | 365.11K | -1.64M | 337.97K | 0.00 | -241.61K | 33.09K | 0.00 | 0.00 |
| Income Before Tax | -15.55M | -4.47M | -2.67M | -1.77M | -760.57K | -7.92M | -8.64M | -3.17M | -922.25K |
| Income Before Tax Ratio | -24.82% | -24.43% | 7,951.30% | -502.04% | -24.17% | -201.17% | -218.93% | -150.58% | -256.89% |
| Income Tax Expense | 57.07K | -101.62K | -101.62K | 613.11K | 0.00 | 135.29K | 26.19K | -74.81K | 230.31K |
| Net Income | -15.60M | -4.37M | -2.67M | -2.34M | -760.57K | -8.06M | -8.66M | -3.09M | -922.25K |
| Net Income Ratio | -24.91% | -23.87% | 7,951.30% | -664.91% | -24.17% | -204.61% | -219.59% | -147.03% | -256.89% |
| EPS | -0.16 | -0.10 | -0.06 | -0.07 | -0.02 | -0.24 | -0.29 | -0.13 | -0.15 |
| EPS Diluted | -0.16 | -0.10 | -0.06 | -0.07 | -0.02 | -0.24 | -0.29 | -0.13 | -0.15 |
| Weighted Avg Shares Out | 73.47M | 43.63M | 43.63M | 33.79M | 33.79M | 33.79M | 29.66M | 24.57M | 6.12M |
| Weighted Avg Shares Out (Dil) | 73.47M | 43.63M | 43.63M | 33.79M | 33.79M | 33.79M | 29.66M | 24.57M | 6.12M |
Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces Debt
Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio of Life Science Products Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio...
Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders
SHIRLEY, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today announced the results from its annual general and special meeting of shareholders held on November 8, 2024 (the “Meeting”) in Shirley,...
Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan
Posts updated corporate presentation to website Reminder: Conference call to be held on August 19 th to discuss Q2 2024 financial results SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT)...
Evome Medical Technologies Reports Second Quarter 2024 Financial Results
SHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, featuring $421,000 in positive Adjusted EBITDA1, a reduction in debt,...
Evome Medical Technologies Retains irlabs for Investor Relations Services
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is pleased to announce it has entered into an agreement ("Agreement") with IR Labs Inc. ("irlabs") to provide the Company with investor...
Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter....
Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported continued progress on its turn-around plan. Evome has grown revenue at its core business unit, Biodex Medical Systems, Inc. (“Biodex”),...
Evome Medical Technologies Punctuates Turn Around Plan with Strong Fourth Quarter Resulting in Positive Annual Adjusted EBITDA for Fiscal Year 2023
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announced today preliminary annual financial results for the year ending December 31, 2023. Because of a strong fourth quarter, the Company generated positive Adjusted...
Evome Medical Engages ICP Securities Inc. for Automated Market Making Services
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “ Company ” or “ Evome ”) (TSXV: EVMT), is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including...
Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announces the appointment of two senior healthcare executives to its Board of Directors.
Source: https://incomestatements.info
Category: Stock Reports